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Introduction
Since the first report of a pregnancy following replace-
ment of frozen-thawed human embryos [1], embryo
cryopreservation has become a routine procedure.
Embryonic cryopreservation has been found to increase
cumulative pregnancy rates and to prevent the risk 
of multiple pregnancies. However, cryopreservation of
human embryos significantly reduces their capacity for
implantation [2].
Successful cryopreservation depends, at least in part,
on the modality of the freeze-thaw procedure. Over the
last decade, methods involving slow [1] and rapid [3]
rates of cooling have been used successfully to cryo-
preserve embryos from a wide range of species. Slow-
rate freezing protocols employing controlled rate freezers
for gradual reduction of temperatures below −30ºC
have traditionally been used to freeze embryos in the
clinical laboratory. Various cryoprotectant solutions
have been utilized for dehydration; however, the effi-
cacies of these solutions depend on the stage of the
embryo. In 1985, Lassalle et al [4] described success-
ful cryopreservation with a solution containing 1,2-
propanediol (PROH) and cooling to −30ºC. Since then,
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slow cooling has become the most commonly used
approach for cryopreservation of pronuclear and early
cleavage (2- to 8-cell) stage embryos [4–6]. Glycerol-
based cryoprotectant solutions have been found to be
helpful for blastocyst cryopreservation [7]. However,
slow-rate freezing procedures require expensive equip-
ment and are considerably time-consuming. Moreover,
in clinically-assisted reproductive technology programs,
only a small number of embryos can be cryopreserved
for an individual patient. For that reason, a faster and
simpler method for cryopreservation of human embryos
is desirable.
Recent attention has been focused on the appli-
cation of vitrification technology to human embryo
cryopreservation. With this technology, embryos sus-
pended in a highly concentrated solution are preserved
in liquid nitrogen without the formation of ice crystals
[8]. Vitrification requires the addition of cryoprotec-
tants at high concentrations and the use of high cool-
ing rates such that the embryo is transformed into a
“glasslike state” [9]. Direct exposure of embryos to liq-
uid nitrogen and introduction of novel carrier systems
that minimize vitrification solution volumes have been
instrumental in achieving the rapid temperature shifts
necessary for the success of this technique [10]. Carrier
systems that have been developed for the vitrification
procedure include the Open Pulled Straw [11], elec-
tron microscope grid [10,12], Flexipet [13], Cryoloop
[14,15] and Cryotop [16].
The advantages of vitrification have been reviewed
[9,17–19]. The elimination of ice crystal formation,
made possible through the increased speed of temper-
ature conduction such that chill-associated injuries are
reduced, represents the principal benefit. A practical
advantage is that the speed of the process minimizes
the time during which the embryo is outside the incu-
bator. The vitrification procedure involves minimal set-
up time, can be performed as needed, and does not
require expensive programmable freezing equipment.
To date, clinical reports of findings with the vitrifi-
cation procedure are limited and have mainly described
oocyte- [20,21] or blastocyst-stage [22–29] cryopreser-
vation. By contrast, cryopreservation of human embryos
at the cleavage stage using vitrification methodology
has not been widely studied [15,30–33]. The present
study was therefore undertaken to evaluate the efficacy
of vitrification of human embryos at the cleavage stage
in terms of embryo survival rate and to determine the
outcomes of this procedure with respect to rates of
implantation and clinical pregnancy. For comparison
purposes, the efficacy and outcomes of cryopreserva-
tion of human cleavage-stage embryos by conventional
slow freezing were also evaluated.
Material and Methods
Patients
A total of 102 subjects were enrolled in this retrospec-
tive study, which was conducted between January 2003
and August 2009. Prior to January 2007, a slow-freezing
protocol was routinely employed for cryopreservation
of human cleavage-stage embryos. The practice of vit-
rification of day 2–3 surplus embryos was initiated in
the clinic in April 2007. The policy of the clinic was 
to perform day 2–3 embryo transfers to patients who
have undergone in vitro fertilization/intracytoplasmic
sperm injection treatments with cryopreservation of
the surplus good quality embryos performed on the
day of transfer. Good quality embryos not selected for
transfer were considered for cryopreservation on day
2–3 if they were 2–4 blastomeres with less than 20%
fragmentation for day 2 and 6–8 blastomeres with less
than 20% fragmentation for day 3.
Ovarian stimulation procedure
Subcutaneous injection of leuprolide acetate (Lupron;
Abbott Laboratories, Chicago, IL, USA) for pituitary
desensitization was initiated on the 20th day of the men-
strual cycle with daily injections continued until human
chorionic gonadotrophin (hCG; Pregnyl; Organon, Oss,
the Netherlands) was administered. Gonadotrophins, a
combination of menotrophin (Menopur; Ferring, GmbH,
Germany) and recombinant follicle stimulation hormone
(r-FSH; Gonal-F; Serono, Aubonne, Switzerland), were
administered intramuscularly from the third day of the
menstrual cycle (once daily). The r-FSH and meno-
trophin dosages were adjusted for each subject accord-
ing to the ovarian response to stimulation. Beginning
with the seventh day of the menstrual cycle, transvagi-
nal ultrasonography was performed once daily or every
other day to monitor follicular growth. When two or
three dominant follicles reached a mean diameter of
19 mm, ovulation was induced with 10,000 IU of hCG.
Transvaginal ovum pick-up was then performed under
ultrasonographic guidance 34–36 hours later.
Slow-freezing and thawing procedures
Embryos were first placed in equilibration solution
comprising 1.5 M PROH in phosphate-buffered saline,
supplemented with 20% (v/v) maternal serum at room
temperature for 5 minutes and then transferred to a
freezing solution (1.5 M PROH and 0.2 M sucrose) in
phosphate-buffered saline supplemented with 20%
maternal serum for an additional 5 minutes. Following
exposure to the final freezing solution, embryos were
transferred to 0.25 mL plastic straws and placed in a
programmable freezer (Kryo 10 series; Planar Products,
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Sunbury Thames, UK) for cooling. Embryos were cooled
at rate of −2ºC/min to −7ºC. Ice crystal formation was
then induced by placing the straw in contact with a
metal object that had been cooled in liquid nitrogen for
seeding. Cooling was continued at a rate of −0.3ºC/
min to −30°C, and the straw was then plunged into
liquid nitrogen for storage. For the thawing process,
the straw was removed from storage, held at ambient
temperature for 6 seconds, and immersed in a water
bath at 37ºC for 30–40 seconds. For the dilution 
procedure, embryos were transferred to the following
solutions in series and held in each for 5 minutes at
room temperature: 1.0 M PROH containing 0.2 M
sucrose, 0.5 M PROH containing 0.2 M sucrose, and
0.2 M sucrose. Embryos were then transferred to
sucrose-free medium and held at room temperature
for 5 minutes.
Vitrification and thawing procedure
Beginning in March 2007, vitrification was employed
as the routine strategy for cryopreservation of human
cleavage-stage embryos. Vitrification of surplus embryos
was performed according to the two-step protocol of
Mukaida et al [30]. This technique involves the use of
dimethylsulphoxide (DMSO), ethylene glycol, and suc-
rose as cryoprotective agents. All steps were performed
in a laminar flow hood at room temperature. Embryos
were incubated in Vitrification Solution #1, which con-
sisted of 7.5% (v/v) DMSO and 7.5% (v/v) ethylene 
glycol, for 5–6 minutes during which the appropriate
morphological changes were observed. Embryos were
then moved to Vitrification Solution #2, which was
comprised of 15% (v/v) DMSO, 15% (v/v) ethylene gly-
col, and 0.65 M sucrose and were held for 30 seconds.
With the aid of a fine micropipette and a dissecting
microscope, the embryos were quickly placed onto a
Cryotop (Kitazato Supply Co., Fujinomiya, Japan), fol-
lowed by aspiration of excess medium with a fine pipette.
The Cryotop with embryos was then quickly immersed
in liquid nitrogen and the plastic cap was pulled over
the film portion of the Cryotop, followed by continued
storage in liquid nitrogen. For warming, the protective
cover was removed from the Cryotop while it was sub-
merged in liquid nitrogen, and the polypropylene strip
of the Cryotop was immersed directly into 3 mL of 1.0 M
sucrose at 37ºC for 1 minute. Embryos were retrieved
and held for 3 minutes in 1 mL of a dilution solution
consisting of 0.5 M sucrose in TCM199 medium con-
taining 20% serum substitute supplement, followed by
two washes with TCM199 medium supplemented with
20% serum substitute supplement for 5 minutes each
at room temperature. Embryos were then subjected to
culture as detailed below.
Assessment of embryo survival
After thawing, embryos were placed in culture medium
(Cleavage medium; SAGE, BioPharma, USA) supple-
mented with 10% serum protein substitute under oil 
at 37ºC in an atmosphere containing 5% O2, 5% CO2,
and 90% N2 and immediately evaluated for integrity
and number of surviving blastomeres. Embryos were
considered to have survived if at least half of their blas-
tomeres were intact after thawing. Surviving embryos
were incubated at 37ºC for an additional 4–6 hours
during which time subjects were prepared for transfer.
Patients were prepared for frozen-warmed embryo
transfer using hormone replacement therapy consisting
of increasing doses of estromon (2.5–5 mg p.o. daily)
and progesterone (Utrogestan, 200 mg, 3 times daily)
for luteal supplementation. Pregnancy was confirmed by
measuring serum β-hCG levels 12–13 days after embryo
transfer. An intrauterine gestational sac with active
fetal heart beat as visualized on ultrasound examina-
tion 6 weeks after embryo transfer was considered to be
a clinical pregnancy. The implantation rate was derived
from the number of gestational sacs divided by the
total number of embryos transferred. Multiple preg-
nancies were defined as a gestation with more than
one gestational sac. Ongoing pregnancy was defined
as pregnancy proceeding beyond the 12th gestational
week. Abortion was defined as fetal loss at less than
12 weeks of gestation.
Statistical analysis
The vitrification and slow freezing protocols were com-
pared with respect to rates of post-thaw embryo sur-
vival, implantation, and pregnancy using χ2 analysis.
Patient age and number of embryos transferred per
cycle were compared using the Student’s t test. A p value
of < 0.05 was considered statistically significant.
Results
Table 1 presents the characteristics of patients in their
last fresh assisted reproductive technology (ART) cycle
for the vitrification and slow-freezing groups. The per-
centages of in vitro fertilization and intracytoplasmic
sperm injection cycles were found to be similar between
the two groups. Moreover, no significant differences in
the percentages of patients with each infertility indication
or in the number of previous ART cycles were observed
between the two groups. However, the mean age of
patients was significantly higher in the vitrification group
(33.1 ± 4.0 years vs. 31.1 ± 3.9 years; p = 0.010). The clin-
ical outcomes of the frozen-thawed cleavage-stage em-
bryos for the vitrification and slow-freezing groups are 
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summarized in Table 2. The mean number of thawed
embryos was significantly lower in the vitrification as
compared to the slow-freezing group (5.05 ± 1.86 vs.
9.91 ± 3.83; p < 0.001) whereas the survival rate per
thawed embryo was significantly higher in the vitrifica-
tion as compared to the slow-freezing group (96.4% vs.
65.9 %; p < 0.001). Despite the lower mean number of
embryos selected for transfer in the vitrification group
(2.86 ± 1.11 vs. 3.44 ± 0.89; p = 0.005), the clinical
pregnancy and implantation rates were significantly
higher as compared with those for the slow-freezing
group (35.6% vs. 15.6%, p = 0.040; and 24.3% vs. 7.1%,
p < 0.001). To date, 16 healthy infants have been born
and two miscarriages have occurred in each group, and
no congenital anomalies have been observed.
Discussion
Relatively few studies evaluating the clinical outcomes
for human cleavage-stage embryos subjected to vitrifica-
tion as compared to slow freezing have been performed
[15,33,34]. Zheng et al [34] reported higher survival
of biopsied 8-cell stage embryos following vitrifica-
tion as compared with slow freezing (94% vs. 15%).
However, no statistical difference was observed between
the groups with respect to development to the blas-
tocyst stage. In a larger clinical study, Kuwayama et al
[25] observed significant improvement of 4-cell stage
embryo survival following cryotop vitrification as com-
pared with slow freezing (98% vs. 91%). However, these
investigators reported similar pregnancy rates per trans-
fer for vitrification and slow freezing (27% and 32%,
respectively). Rama Raju et al [15] reported higher
survival of human 8-cell embryos following cryoloop
vitrification as compared to slow freezing (95% vs. 60%)
and observed significantly better implantation and preg-
nancy rates for the vitrification as compared with the
slow freezing group. In the present study, an overall
embryo survival rate of 96.4%, a clinical pregnancy
rate of 35.6%, and an implantation rate of 24.3% was
observed using the cryotop vitrification procedure.
Moreover, warming was required for fewer embryos in
the vitrification was compared to the slow freezing group;
Table 1. Characteristics of patients in the last fresh assisted reproductive technology cycle*
Variable Vitrification (n = 57) Slow-freezing (n = 45) p
Age (yr) 33.1 ± 4.0 31.1 ± 3.9 0.010
IVF cycles 23 (40.4) 13 (28.9) 0.320
ICSI cycles 34 (59.6) 32 (71.1) 0.320
Infertility factor
Male 5 (8.8) 8 (17.8) 0.165
Female 14 (24.6) 18 (40.0) 0.199
Combined 38 (66.7) 19 (42.2) 0.019
Previous ART cycles 0.4 ± 0.6 0.3 ± 0.6 0.858
Supernumerary embryos 6.0 ± 3.1 10.3 ± 4.8 < 0.001
*Data are presented as n (%) or mean ± standard deviation, analyzed by c2 test and student’s t test, respectively. ART = assisted reproductive technology; IVF =
in vitro fertilization; ICSI = intracytoplasmic sperm injection.
Table 2. Clinical outcomes of human cleavage-stage embryo transfer after cryopreservation with the vitrification and 
slow-freezing methods*
Outcome Vitrification Slow-freezing p
Cycles 59 45
Embryos warmed 298 (5.05 ± 1.86) 446 (9.91 ± 3.83) < 0.001
Cryosurvival 287/298 (96.4) 294/446 (65.9) < 0.001
Embryos transferred 169 (2.86 ± 1.11) 155 (3.44 ± 0.89) < 0.005
Implantation rate 41/169 (24.3) 11/155 (7.1) < 0.001
Clinical pregnancy rate 21/59 (35.6) 7/45 (15.6) 0.040
Multiple pregnancy rate 13/21 (61.9) 3/7 (42.9) 0.659
Ongoing pregnancies 20/59 (33.9) 6/45 (13.3) 0.030
Abortions 1/21 (4.8) 1/7 (14.3) 0.397
Deliveries 8 (3 twins, 5 singletons) 5 (5 singletons)
*Data are presented as n (mean ± standard deviation) or n (%), analyzed by student’s t test and c2 test, respectively.
patients in the vitrification group had an increased op-
portunity to receive all post-thawed embryos because
of the higher survival rate per total warmed embryo
(96.4% for the vitrification as compared to 65.9% for
the slow freezing group). To compensate for the poor
survival rate of the slow frozen-thawed embryos and
to increase the chances of successful pregnancy with
these embryos, it was necessary to increase the num-
ber of embryos for the transfer. Regardless, the clinical
outcomes of pregnancy and implantation rates were
found to increase significantly in the vitrification group
(35.6% and 25.3%, respectively) as compared to the
slow freezing group (15.6% and 7.1%, respectively).
Successful vitrification mandates that ice crystal
formation be avoided. Factors necessary for successful
vitrification have been previously determined to include
a faster cooling rate, a high viscosity cryoprotectant
solution, and a small vitrification solution volume [8,35].
Theoretically, minimizing the volume of the vitrifica-
tion solution containing the embryos not only permits
increases in both cooling and warming rates but also
decreases the chance of ice crystal formation [8]. To
decrease the volume of the vitrification solution, Arav
et al [36] developed a vitrification method for imma-
ture bovine oocytes that involved a “minimum drop
size” of 0.1–0.5 μL droplets which were loaded onto
glass coverslip strips and immersed in liquid nitrogen
or nitrogen slush. Cryotops can also be adapted for
reduction in vitrification solution volume [16]. The
solution volume within the thin film strip in a Cryotop
is less than 0.1 μL. In the present study, the Cryotop
was modified for cleavage-stage embryo vitrification
and the cryopreservation solution volume used during
the vitrification process was made sufficiently small to
reduce the potential damage to the embryo during the
freezing process [16], thereby increasing the chances for
a successful outcome.
A notable advantage of vitrification as compared
to the conventional slow-freezing methods is the very
short time period (seconds) required for embryos to
cool; with the vitrification procedure embryos freeze
almost immediately, well before extracellular crystal for-
mation can occur. Osmotic effects and chilling injuries
are therefore virtually eliminated [11]. In contrast, pro-
grammed slow-freezing procedures require a mini-
mum of 2 hours per run and several freezer units to
accommodate cryopreservation for a large number of
patients.
A major finding of the present study was the remark-
ably low percentage (3.6%) of embryos with significant
cellular damage after application of the vitrification
technique. By contrast, with the conventional slow-
freezing protocol using cryostraws, almost one-third
of the surviving embryos exhibited damage in excess of
50%. This degree of damage was associated with blas-
tomere loss and degeneration. In this regard, it should
be noted that blastomere loss in frozen-thawed early
cleavage-stage embryos is strongly associated with a
reduction in implantation potential [37]. Frozen embryo
transfer cycles in which all transferred embryos remain
fully intact at thawing achieve a better outcome than
those in which at least one partially damaged embryo
is transferred [38,39]. Moreover, reduced rates of preg-
nancy [40] and implantation [41] have been linked to
transfer of embryos that are partially damaged after
thawing.
Despite the consistently good findings with the 
vitrification technique, certain concerns remain. For
example, contamination of embryos by viruses present
in liquid nitrogen storage vessels is possible [42–45].
However, the findings of Kyuwa et al [43] revealed that
such cross-contamination is unlikely. These investiga-
tors observed no viral contamination of mouse 2-cell
embryos stored for one year in cryotubes in a liquid
nitrogen vessel in which cryotubes containing mouse
hepatitis virus or Pasteurella pneumotropica were also
stored. Although the potential for microbial contami-
nation of embryos stored in liquid nitrogen vessels also
exists, current findings are inconsistent with the likeli-
hood of such contamination [43,45].
Because vitrification is a relatively new cryopreser-
vation method, prenatal outcome is a major concern.
At the time of this writing, eight of the 21 pregnancies
resulting from embryo transfers performed in this study
have resulted in the births of 11 healthy babies. In the
single largest study addressing this issue [46], the neona-
tal outcome of 817 nylon loop vitrified-warmed day 
3 embryo transfers was compared with that of 1,576
fresh day 3 embryo transfers. No statistical differences
were observed with respect to mean gestational age,
mean birth weight, congenital birth defect rate, and
karyotypic abnormalities. Although these findings are
encouraging, follow-up studies are necessary to ensure
that the vitrification approach for cryopreservation is
truly safe.
In conclusion, the high rates of embryo survival,
implantation, and clinical pregnancy that follow cryop-
reservation of human cleavage-stage embryos by vitrifi-
cation render this approach superior to cryopreservation
of these embryos by conventional slow-freezing.
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